We are live on ! Find out more
SRPT icon

Sarepta Therapeutics
SRPT

179 hedge funds and large institutions have $1.21B invested in Sarepta Therapeutics in 2017 Q1 according to their latest regulatory filings, with 39 funds opening new positions, 64 increasing their positions, 44 reducing their positions, and 28 closing their positions.

New
Increased
Maintained
Reduced
Closed

97% more call options, than puts

Call options by funds: $108M | Put options by funds: $54.9M

45% more repeat investments, than reductions

Existing positions increased: 64 | Existing positions reduced: 44

39% more first-time investments, than exits

New positions opened: 39 | Existing positions closed: 28

11% more capital invested

Capital invested by funds: $1.08B → $1.21B (+$123M)

2.09% more ownership

Funds ownership: 72.29% → 74.38% (+2.1%)

1% more funds holding

Funds holding: 177 → 179 (+2)

50% less funds holding in top 10

Funds holding in top 10: 4 → 2 (-2)

Holders
179
Holders Change
+2
Holders Change %
+1.13%
% of All Funds
4.46%
Holding in Top 10
2
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-50%
% of All Funds
0.05%
New
39
Increased
64
Reduced
44
Closed
28
Calls
$108M
Puts
$54.9M
Net Calls
+$53.5M
Net Calls Change
+$36.4M

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$160M
2
HM
HealthCor Management
New York
+$48M
3
CCM
Camber Capital Management
Massachusetts
+$41.8M
4
O
OrbiMed
New York
+$32.6M
5
PC
PointState Capital
New York
+$19.8M

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$62.4M
2
PA
Perceptive Advisors
New York
-$30.9M
3
ACA
Avoro Capital Advisors
New York
-$27.7M
4
JG
Jefferies Group
New York
-$26M
5
Point72 Asset Management
Point72 Asset Management
Connecticut
-$17.5M
Name Holding Trade Value Shares
Change 		Change in
Stake
CSS
151
Cubist Systematic Strategies
Connecticut
$63K -$87.1K -2,813 -57%
FPF
152
FNY Partners Fund
New York
$59K -$115K -3,700 -65%
GT
153
Glenmede Trust
Pennsylvania
$59K – – –
MFW
154
Mosaic Family Wealth
Missouri
$56K – – –
LTFS
155
Ladenburg Thalmann Financial Services
Florida
$50K +$15.4K +498 +41%
WEC
156
Winslow Evans & Crocker
Massachusetts
$38.5K -$21.7K -700 -35%
Zurich Cantonal Bank
157
Zurich Cantonal Bank
Switzerland
$38K – – –
BNP Paribas Financial Markets
158
BNP Paribas Financial Markets
France
$35K -$22.3K -721 -38%
CLOS
159
Compagnie Lombard Odier SCmA
Switzerland
$24K -$24.8K -800 -50%
IA
160
IFP Advisors
Florida
$24K -$19.1K -616 -43%
NSIM
161
North Star Investment Management
Illinois
$22K – – –
KF
162
Krilogy Financial
Missouri
$18K – – –
SPIA
163
Steward Partners Investment Advisory
New York
$14K +$15.5K +500 New
Envestnet Asset Management
164
Envestnet Asset Management
Illinois
$13K -$5.01K -162 -28%
GWM
165
Geneos Wealth Management
Colorado
$13K +$7.74K +250 +124%
AF
166
Allworth Financial
California
$12K – – –
PSC
167
Prentiss Smith & Co
Vermont
$12K – – –
Nisa Investment Advisors
168
Nisa Investment Advisors
Missouri
$9K -$8.67K -280 -47%
FMA
169
FNY Managed Accounts
New York
$8K +$9.29K +300 New
LJHT
170
Laurie J. Hall Trustee
$3.8K +$4.02K +130 New
GBBWRPM
171
Genovese Burford & Brothers Wealth & Retirement Plan Management
California
$3K – – –
MAM
172
Meeder Asset Management
Ohio
$3K +$3.19K +103 New
CHP
173
Cable Hill Partners
Oregon
$3K +$3.28K +106 New
FDCDDQ
174
Federation des caisses Desjardins du Quebec
Quebec, Canada
$2.96K +$3.1K +100 New
PCA
175
Peddock Capital Advisors
Massachusetts
$2K – – –
5 6
7
8 9

SRPT Hedge Fund Activity: Q1 2017 in Review

179 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Sarepta Therapeutics (SRPT) for Q1 2017, worth a combined $1.21B — up 11% from $1.08B a quarter earlier.

Buyers outnumbered sellers: 39 funds opened new SRPT positions and 28 closed out — a net gain of 11 holders — while 64 added to existing stakes and 44 trimmed.

The largest buyer was BlackRock, adding an estimated $160M. The largest seller was Sabby Management, exiting entirely with an estimated $62.4M sold.

  • 179 institutional investors held Sarepta Therapeutics (SRPT) as of Q1 2017, up from 177 in Q4 2016.
  • Funds reported $1.21B of Sarepta Therapeutics stock for Q1 2017, up 11% quarter-over-quarter.
  • 39 funds opened new Sarepta Therapeutics positions in Q1 2017 and 28 closed out, a net change of +11 holders.
  • The largest Sarepta Therapeutics buyer in Q1 2017 was BlackRock, an estimated $160M added.
  • The largest Sarepta Therapeutics seller in Q1 2017 was Sabby Management, an estimated $62.4M sold.

Based on aggregated 13F filings for Q1 2017.